Search results
Results from the WOW.Com Content Network
Donepezil is a centrally acting reversible acetylcholinesterase inhibitor and structurally unrelated to other anticholinesterase agents. [8] [5] Common side effects include nausea, trouble sleeping, aggression, diarrhea, feeling tired, and muscle cramps. [8] [11] Serious side effects may include abnormal heart rhythms, urinary incontinence, and ...
Side-effects of the donanemab, and other similar drugs, can be serious. Donanemab has been linked to “amyloid-related imaging abnormalities (Aria)” which does not usually cause symptoms but ...
Donanemab, sold under the brand name Kisunla, is a monoclonal antibody used for the treatment of Alzheimer's disease. [1] [2] Donanemab was developed by Eli Lilly and Company. [3] [4] The most common side effects include amyloid-related imaging abnormalities and headache. [2] Donanemab was approved for medical use in the United States in July 2024.
Donanemab, sold under the brand name Kisunla, is a monoclonal antibody used for the treatment of Alzheimer's disease. [31] [32] Donanemab was developed by Eli Lilly and Company. [33] [34] The most common side effects include amyloid-related imaging abnormalities and headache. [32] Donanemab was approved for medical use in the United States in ...
The MHRA may not approve donanemab due to concerns regarding risk of side-effects, according to the report. Both the drugs have been approved for use in the United States.
The study, published in the Journal of the American Medical Association, concluded that after 76 weeks of treatment, Donanemab was able to slow clinical decline by 35.1% in people with early ...
[4] [5] Side effects when used as drugs may include loss of appetite, nausea, vomiting, loose stools, vivid dreams at night, dehydration, rash, bradycardia, peptic ulcer disease, seizures, weight loss, rhinorrhea, salivation, muscle cramps, and fasciculations. [6] [7] ChEIs are indirect-acting parasympathomimetic drugs. [8]
The FDA was initially set to decide about the treatment in March but delayed the decision in order to get more guidance from its advisory panel on whether the benefits outweighed the side effects.